Sucralfate 1 g Tablet, 500-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Aluminum Complex class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Sucralfate helps heal a duodenal ulcer — that's an ulcer in the first part of your small intestine. It works by coating the ulcer like a protective bandage, shielding it from stoma...
- What exactly is sucralfate supposed to do for me?
- Yes, timing really does matter. You should take sucralfate on an empty stomach so it can stick directly to the ulcer lining. Taking it with food can get in the way of that. If you...
- When should I take sucralfate — does it matter if I take it with food?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Sucralfate — tap one for details:
Sucralfate may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.173 | $86.25 / 500 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2473 | $123.65 / 500 tablets |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Sucralfate 1 g 00093-2210-01 | Teva | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 51079-0753-20 | Mylan | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 59762-0401-01 | Mylan | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 60219-1656-01 | Amneal | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 62135-0436-90 | Chartwell | 90 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 69238-1656-01 | Amneal | 100 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 gthis 72578-0081-05 | Viona | 500 tablets | $0.172 | AB | Availability likely | — |
| Sucralfate 1 g 60687-0695-01 | American | 100 tablets | $0.179 | AB | Discontinued | +4% |
| Carafate 1 g 58914-0171-10 | Allergan, | 100 tablets | $4.733 | AB | Availability likely | +2644% |
| Sucralfate 1 g 00615-4517-30 | NCS | 30 tablets | — | AB | Discontinued | — |
| Sucralfate 1 g 00615-8653-39 | NCS | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 42291-0936-90 | AvKARE | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 48433-0091-20 | Safecor | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 50090-5287-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 50090-6455-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51407-0881-90 | Golden | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51655-0031-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51655-0475-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-4379-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-1307-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9152-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9153-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67046-1469-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67296-2147-04 | Redpharm | 40 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-1749-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3478-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3812-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8316-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8779-03 | Preferred | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8946-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 70771-1833-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2114-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2461-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2637-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0017-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0541-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72162-2264-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0234-20 | DIRECT | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0429-20 | Direct_Rx | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0091-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0188-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0213-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0377-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0063-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0102-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 87063-0176-01 | ASCLEMED | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-0281-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 72578-0081-01 | 100 TABLET in 1 BOTTLE (72578-081-01) | $0.1725 / ea | $17.25 | 2023-05-20 | Active |
| 72578-0081-05 You're viewing this | 500 TABLET in 1 BOTTLE (72578-081-05) | $0.1725 / ea | $86.24 | 2023-05-20 | Active |
| 72578-0081-06 | 30 TABLET in 1 BOTTLE (72578-081-06) | — | — | 2023-05-20 | Active |
You're viewing the largest of 3 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.1725 NADAC).
This pack accounts for about 29% of this product's recent Medicaid fills; most go to the 100 tablets pack. See all packs ↓
Pack size FAQ
What quantity is in NDC 72578-0081-05?
What is the difference between NDC 72578-0081-05 and NDC 72578-0081-06?
What NDC number is used to bill for this package of Sucralfate 1 g Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day. Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS Geriatric Use ).
Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
⛔ Contraindications ▾
CONTRAINDICATIONS Sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%).
Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria. Cases of anaphylactic reactions, bronchospasm, laryngeal edema, edema of the mouth, pharyngeal edema, respiratory tract edema and swelling of the face have been reported with an unknown oral formulation of sucralfate.
Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli.
Sucralfate is not intended for inteavenous administration.
🆘 Overdosage ▾
OVERDOSAGE Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract.
Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action.
The following observations also appear pertinent: 1. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. 2.
In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. 3. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
4. In vitro, sucralfate adsorbs bile salts. These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts.
There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Sucralfate tablets USP, 1g are supplied as follows: NDC 72578-081-06 in bottles of 30 tablets with child-resistant closure NDC 72578-081-01 in bottles of 100 tablets with child-resistant closure NDC 72578-081-05 in bottles of 500 tablets White to off-white, capsule shaped, biconvex, scored, uncoated tablets, debossed with "6" and "75" on either side of score and plain on other side. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Rx Only Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India Distributed by: Viona Pharmaceuticals Inc.
Cranford, NJ 07016 Rev.: 11/2023
📋 Description ▾
DESCRIPTION Sucralfate tablets, USP contain sucralfate USP and sucralfate is an α-D-glucopyranoside, β-D fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. Tablets for oral administration contain 1 g of sucralfate, USP. Also contain: magnesium stearate, microcrystalline cellulose, and corn starch. Therapeutic category: antiulcer. figure